Latest news with #PulmonaryFibrosis
Globe and Mail
6 days ago
- Business
- Globe and Mail
Pulmonary Fibrosis Pipeline Outlook Report 2025: Key 110+ Companies and Breakthrough Therapies Shaping the Future Landscape
DelveInsight's, 'Pulmonary Fibrosis Pipeline Insight 2025' report provides comprehensive insights about 110+ companies and 140+ pipeline drugs in Pulmonary Fibrosis pipeline landscape. It covers the Pulmonary Fibrosis Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Pulmonary Fibrosis Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Discover the latest drugs and treatment options in the Pulmonary Fibrosis Pipeline. Dive into DelveInsight's comprehensive report today! @ Pulmonary Fibrosis Pipeline Outlook Key Takeaways from the Pulmonary Fibrosis Pipeline Report In August 2025, InSilico Medicine Hong Kong Limited announced a clinical trial is to learn about INS018_055 in adults with Idiopathic Pulmonary Fibrosis (IPF). The primary objective is to evaluate the safety and tolerability of INS018_055 orally administered for up to 12 weeks in adult subjects with IPF compared to placebo. In August 2025, Daewoong Pharmaceutical Co. Ltd conducted a phase 2 study to evaluate the Safety and Efficacy of DWN12088 in Patients With Idiopathic Pulmonary Fibrosis. DelveInsight's Pulmonary Fibrosis Pipeline report depicts a robust space with 110+ active players working to develop 140+ pipeline therapies for Pulmonary Fibrosis treatment. The leading Pulmonary Fibrosis Companies such as Bristol-Myers Squibb, Ark Biosciences Inc., PureTech Health, Sarepta Therapeutics, Toray Industries, Inc., Wuhan Optics Valley Vcanbiopharma Co., Ltd., Nitto Denko, Syndax Pharmaceuticals, Endeavor BioMedicines, AstraZeneca, Pulmongene Ltd., BreStem Therapeutics, Nuformix, AbbVie, Saniona and others. Promising Pulmonary Fibrosis Pipeline Therapies such as BMS-986278, Pirfenidone, Etanercept, BI 1839100, CNTO 888 1 mg/kg, Nintedanib, Pirfenidoneone and others. Stay ahead with the most recent pipeline outlook for Pulmonary Fibrosis. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Pulmonary Fibrosis Treatment Drugs Pulmonary Fibrosis Emerging Drugs Profile BMS-986278: Bristol-Myers Squibb BMS-986278 is a potential first-in-class, oral, small molecule lysophosphatidic acid receptor 1 (LPA1) antagonist currently being evaluated as a novel antifibrotic treatment for patients with idiopathic pulmonary fibrosis and progressive pulmonary fibrosis. Increased LPA levels and activation of LPA are involved in the pathogenesis of pulmonary fibrosis. BMS-986278 is a potent and complete antagonist of LPA action at LPA1-mediated Gi, Gq, G12, and β-arrestin signaling pathways in both cells heterologously expressing human LPA1 and in primary human lung fibroblasts. The drug is currently in Phase III stage of clinical trial evaluation for the treatment of pulmonary fibrosis. AK3280: Ark Biosciences Inc. AK3280 is a next-generation broad-spectrum anti-fibrotic molecule optimized from the marketed drug pirfenidone. It has the ability to modulate multiple pathways and biomarkers closely associated with the fibrotic process, including the expression of fibrosis-related genes and proteins induced by transforming growth factor-beta (TGF-B) and lysophosphatidic acid (LPA). AK3280 works by reducing cell proliferation and inhibiting the synthesis and accumulation of extracellular matrix. Compared to pirfenidone, AK3280 offers advantages in safety and tolerability, with potentially much better clinical efficacy. The drug is currently in Phase II stage of clinical trial evaluation for the treatment of pulmonary fibrosis. LYT-100: PureTech Health LYT-100 (deupirfenidone) is currently in development for idiopathic pulmonary fibrosis (IPF), which is a rare, progressive and fatal disease. LYT-100 is a deuterated form of pirfenidone and is designed to retain the beneficial pharmacology and clinically-validated efficacy of pirfenidone with a highly differentiated pharmacokinetic (PK) profile. In multiple clinical trials, LYT-100 has demonstrated a favorable tolerability profile, which may keep patients on treatment longer to enable more optimal disease management. The drug is currently in Phase II stage of clinical trial evaluation for the treatment of pulmonary fibrosis. ARO-MMP7: Sarepta Therapeutics ARO-MMP7 is an investigational RNA interference (RNAi) therapeutic developed by Arrowhead Pharmaceuticals, aimed at treating idiopathic pulmonary fibrosis (IPF) by targeting and reducing the expression of matrix metalloproteinase 7 (MMP7). This protein is implicated in the pathogenesis of IPF, contributing to inflammation and fibrosis in the lungs. The drug is currently in Phase I/II stage of clinical trial evaluation for the treatment of pulmonary fibrosis. TRK-250: Toray Industries, Inc TRK-250, also known as BNC-1021, is a nucleic acid medicine developed by Toray Industries in collaboration with BONAC Corporation. It is designed to treat Idiopathic Pulmonary Fibrosis (IPF). The drug works by selectively inhibiting the expression of transforming growth factor-beta 1 (TGF-β1), a key protein involved in the fibrotic process at the gene expression level. The drug is currently in Phase I stage of clinical trial evaluation for the treatment of pulmonary fibrosis. VUM02: Wuhan Optics Valley Vcanbiopharma Co., Ltd. VUM02 Injection is an innovative therapeutic product developed by Wuhan Optics Valley Vcanbiopharma Co., Ltd. It utilizes human umbilical cord-derived mesenchymal stem cells (hUCT-MSCs). The drug is currently in Phase I stage of clinical trial evaluation for the treatment of pulmonary fibrosis. The Pulmonary Fibrosis Pipeline Report Provides Insights into The report provides detailed insights about companies that are developing therapies for the treatment of Pulmonary Fibrosis with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Pulmonary Fibrosis Treatment. Pulmonary Fibrosis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Pulmonary Fibrosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Pulmonary Fibrosis market Explore groundbreaking therapies and clinical trials in the Pulmonary Fibrosis Pipeline. Access DelveInsight's detailed report now! @ New Pulmonary Fibrosis Drugs Pulmonary Fibrosis Companies Bristol-Myers Squibb, Ark Biosciences Inc., PureTech Health, Sarepta Therapeutics, Toray Industries, Inc., Wuhan Optics Valley Vcanbiopharma Co., Ltd., Nitto Denko, Syndax Pharmaceuticals, Endeavor BioMedicines, AstraZeneca, Pulmongene Ltd., BreStem Therapeutics, Nuformix, AbbVie, Saniona and others. Pulmonary Fibrosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Oral Intravenous Subcutaneous Parenteral Topical Pulmonary Fibrosis Products have been categorized under various Molecule types such as Small molecule Monoclonal antibody Peptide Polymer Gene therapy Unveil the future of Pulmonary Fibrosis Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Pulmonary Fibrosis Market Drivers and Barriers Scope of the Pulmonary Fibrosis Pipeline Report Coverage- Global Pulmonary Fibrosis Companies- Bristol-Myers Squibb, Ark Biosciences Inc., PureTech Health, Sarepta Therapeutics, Toray Industries, Inc., Wuhan Optics Valley Vcanbiopharma Co., Ltd., Nitto Denko, Syndax Pharmaceuticals, Endeavor BioMedicines, AstraZeneca, Pulmongene Ltd., BreStem Therapeutics, Nuformix, AbbVie, Saniona and others. Pulmonary Fibrosis Pipeline Therapies - BMS-986278, Pirfenidone, Etanercept, BI 1839100, CNTO 888 1 mg/kg, Nintedanib, Pirfenidoneone and others. Pulmonary Fibrosis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Pulmonary Fibrosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Get the latest on Pulmonary Fibrosis Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Pulmonary Fibrosis Companies, Key Products and Unmet Needs Table of Content Introduction Executive Summary Pulmonary Fibrosis: Overview Therapeutic Assessment Pulmonary Fibrosis– DelveInsight's Analytical Perspective Late Stage Products (Phase III) BMS-986278: Bristol-Myers Squibb Drug profiles in the detailed report….. Mid Stage Products (Phase II) AK3280: Ark Biosciences Inc. Drug profiles in the detailed report….. Early Stage Products (Phase I) VUM02: Wuhan Optics Valley Vcanbiopharma Co., Ltd. Drug profiles in the detailed report….. Preclinical and Discovery Stage Products RSBT 001: RS BioTherapeutics Drug profiles in the detailed report….. Inactive Products Pulmonary Fibrosis Key Companies Pulmonary Fibrosis Key Products Pulmonary Fibrosis- Unmet Needs Pulmonary Fibrosis- Market Drivers and Barriers Pulmonary Fibrosis- Future Perspectives and Conclusion Pulmonary Fibrosis Analyst Views Pulmonary Fibrosis Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
Yahoo
16-05-2025
- Health
- Yahoo
ArkBio Announces Positive Phase II Results of AK3280 for Treatment of Idiopathic Pulmonary Fibrosis (IPF)
SHANGHAI, May 16, 2025 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced positive top-line Phase II study results for its novel anti-fibrotic drug AK3280 in treatment of idiopathic pulmonary fibrosis (IPF). The study, led by Professor Huaping Dai of the Department of Pulmonary and Critical Care Medicine at China-Japan Friendship Hospital, Beijing, was conducted across 31 clinical sites in China. Global Clinical Challenge: Unresolved Treatment Needs in IPF Idiopathic Pulmonary Fibrosis (IPF) is a progressive, irreversible, and fatal interstitial lung disease characterized by fibrotic remodeling of lung tissue, ultimately leading to respiratory failure, with a median survival period of only 2–5 years after diagnosis. Current therapeutics including pirfenidone and nintedanib have been available for years, however, with limited efficacy, significant adverse effects and poor long-term tolerability, highlighting the urgent need for novel and more effective therapeutics. Phase 2 Proof-of-Concept Study of AK3280, a New Generation Broadly Active Antifibrotic Drug AK3280 is a new generation broadly active antifibrotic drug that is optimized for pharmacological and pharmacokinetic properties based on current IPF drugs. Preclinical data indicate that it exhibits enhanced anti-fibrotic activity and improved pharmacokinetic properties, without the gastrointestinal tolerability issues and other toxicities associated with current therapeutics. Previous Phase I studies have demonstrated its favorable safety, tolerability, and human pharmacokinetic profile. The completed randomized, double-blind, placebo-controlled Phase II proof-of-concept study evaluated the safety, tolerability and clinical efficacy of AK3280 in China IPF patients. Participants were randomized to receive AK3280 (100/200/300/400 mg BID) or placebo for 24 weeks. Clinical efficacy endpoints included forced vital capacity of lung (FVC and %pFVC), diffusing capacity of lung for carbon monoxide (DLco), the 6-minute walk test (6MWT) and patient reported St. George's Respiratory Questionnaire (SGRQ) scores. The high dose groups demonstrated FVC improvement from baseline, especially the 400 mg group which had the absolute FVC increased by 209.4 mL and a 6.4% adjusted %pFVC improvement from baseline, which is statistically significant compared to placebo (p=0.002 and 0.004, respectively). Other lung and respiratory functions have also got better. The drug exhibited a good safety and tolerability profile without the gastrointestinal intolerability issues associated with current IPF therapeutics. Implications for Future IPF Therapeutics This study with a rigorous multicenter, randomized, double-blind study design for 24 weeks followed by another 24 week's open-label study represents the first phase 2 proof-of-concept study of AK3280 in fibrotic patient populations. These findings not only demonstrate AK3280's potential to improve both lung function and respiratory outcome but also highlight its unique safety profile that may support long-term use, positioning it as a potential future standard-of-care therapy for IPF treatment. Dr. Huaping Dai, principal investigator of the phase 2 study and professor at China-Japan Friendship Hospital, commented, "In the therapeutic landscape of IPF, the development of safer and more effective anti-fibrotic agents remains urgent. The most encouraging aspect of this Phase II study is AK3280's positive signal in pulmonary function improvement. Unlike existing therapies that merely slow FVC decline, the high dosing groups of the phase 2 study achieved an impressive absolute increase in FVC over 24 weeks. In addition, we observed other respiratory and lung function improvements, indicating the substantial symptom relief and benefits to quality-of-life in the IPF patients. Notably, AK3280's favorable tolerability across all dose levels is essential for the long-term management of IPF patients. This study provides novel scientific and medical perspectives, and we look forward to seeing this innovation to become a global standard treatment option in the near future." About AK3280 AK3280 is a potential next-generation broad-spectrum anti-fibrotic molecule optimized from the marketed drug. It modulates multiple pathways and biomarkers closely associated with the fibrotic process, including the expression of fibrosis-related genes and proteins induced by transforming growth factor-beta (TGF-β) and lysophosphatidic acid (LPA). AK3280 works by reducing fibroblast cellular proliferation and inhibiting the synthesis and accumulation of extracellular matrix. Compared to current therapies, AK3280 offers advantages in safety and tolerability, with potentially much improved clinical efficacy. The Phase II randomized, double-blind, placebo-controlled confirmatory clinical study has been completed, and preparations are underway to initiate the pivotal Phase III clinical study. About ArkBio ArkBio is a global biotech company focused on developing innovative therapies for respiratory, infectious, and pediatric diseases. Founded in 2014, it has built core technology platforms and a differentiated R&D pipeline through in-house R&D efforts and external collaboration. Key drug assets include ziresovir, the first direct-acting RSV antiviral with positive pivotal phase III results, and AK0901, an FDA-approved pediatric ADHD therapeutic drug. ArkBio has established strategic partnerships with several multinational pharmaceutical companies and academic institutes, including Roche, Genentech, the Scripps Research Institute, the Institute of Microbiology of Chinese Academy of Sciences, domestic and international biotechnology companies, as well as venture capital institutions. For more information about the company, please visit our website: Investor Inquiries: IR@ View original content to download multimedia: SOURCE Arkbio Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
02-04-2025
- Health
- Yahoo
Endeavor BioMedicines Appoints Internationally Renowned ILD Expert Lisa Lancaster, M.D., as Chief Medical Officer
SAN DIEGO, April 02, 2025--(BUSINESS WIRE)--Endeavor BioMedicines, a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients with life-threatening diseases, today announced the appointment of Lisa Lancaster, M.D., as Chief Medical Officer. A renowned pulmonologist and clinical researcher focused on interstitial lung disease (ILD), Dr. Lancaster will lead the company's clinical development program for ENV-101 (taladegib), an inhibitor of the Hedgehog signaling pathway for the treatment of pulmonary fibrosis. "Dr. Lancaster is a highly experienced and respected physician with extensive expertise in interstitial lung diseases, including idiopathic pulmonary fibrosis," said John Hood, Ph.D., Co-founder, CEO and Chairman, Endeavor BioMedicines. "Her background, in addition to her deep relationships within the pulmonology community, make her the ideal candidate to fill the chief medical officer role. We are thrilled to have her join the Endeavor team." Dr. Lancaster has 25 years of pulmonology experience, serving as Interstitial Lung Disease Program Director at Vanderbilt University Medical Center since 2000, as well as Professor of Medicine in the Division of Allergy, Pulmonary and Critical Care Medicine within the Department of Medicine at Vanderbilt University Medical Center. Since Dr. Lancaster joined Vanderbilt University Medical Center in 1999, the Vanderbilt Idiopathic Pulmonary Fibrosis and ILD Research Program has participated in and/or completed over 80 clinical trials and registries. This included Dr. Lancaster serving as a principal investigator for pivotal clinical trials evaluating the two currently approved idiopathic pulmonary fibrosis therapies. Dr. Lancaster has also served on numerous ILD steering committees and advisory boards and has authored or coauthored over 100 publications on ILD. Her national leadership roles have included membership in the Steering Committee for the Diffuse Lung Disease Network of the American College of Chest Physicians and the Steering Committee for the Pulmonary Fibrosis Foundation Registry. "As a physician who has spent my entire career treating patients and leading clinical research programs, it is profoundly important to me to work among colleagues who share my passion for restoring hope for patients and their families living with IPF," said Dr. Lancaster. "At Endeavor, I have found just that – a team who strives to push the boundaries of medical innovation to create meaningful new therapeutic options for these patients." About Endeavor BioMedicines Endeavor BioMedicines is a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients with life-threatening diseases. Endeavor's lead candidate, ENV-101 (taladegib), is an inhibitor of the Hedgehog signaling pathway in development for fibrotic lung diseases, including idiopathic pulmonary fibrosis (IPF). The company's second candidate, ENV-501, is a HER3 antibody-drug conjugate (ADC) in development for the treatment of HER3-positive solid tumors. More information is available at and on LinkedIn or X. View source version on Contacts Media Contact: Audra Friis Sam Brown, Inc.917-519-9577audrafriis@ Sign in to access your portfolio
Yahoo
27-02-2025
- Health
- Yahoo
Enniskillen retreat provides support for those battling Pulmonary Fibrosis
A new retreat providing respite for individuals and families affected by Pulmonary Fibrosis has officially opened in Enniskillen. Inis Ceithleann Retreat was launched in a heartfelt ceremony, marking a significant milestone for the Pulmonary Fibrosis community in Northern Ireland. Speaking at the opening, Clare Donohoe, Trustee of Pulmonary Fibrosis NI (PFNI), described the moment as both an honour and a deeply personal one. The retreat, she explained, is more than just a building; it is a sanctuary offering relief to those facing the challenges of the disease. 'For me, today is also bittersweet,' she shared, reflecting on her late husband Tom's battle with Idiopathic Pulmonary Fibrosis (IPF). Tom, a devoted husband and father, was diagnosed in 2019 at the age of 43 after initially presenting with a persistent cough. 'Devastation hit home when I researched the disease,' Mrs. Donohoe said, recounting the impact on their young family. Despite the challenges, Tom remained stoic and hopeful, continuing to work while quietly managing his diagnosis. In June 2024, Mrs. Donohoe took voluntary redundancy from her role as a lecturer to care for Tom as he navigated the later stages of the disease while awaiting a transplant at The Freeman Hospital in Newcastle. However, the transplant never came. In August 2024, Tom's condition worsened, and after three weeks in intensive care at the South West Acute Hospital, he passed away on September 1. Despite her grief, his wife emphasised Tom's instrumental role in securing the property for Inis Ceithleann Retreat. A chance conversation with a workman during a drive led to an introduction to the owner, David Wilson, and eventually, the acquisition of the property by PFNI in June 2024. 'Whilst Tom's loss is deeply felt, his legacy lives on in the sanctuary of Inis Ceithleann Retreat, and in the hope and respite it will offer to so many who sadly are on the pulmonary fibrosis journey,' she said. Mrs. Donohoe extended heartfelt thanks to the many supporters, trustees, funders, and friends who made the retreat possible. She also acknowledged Paul Shannon, William Foster, and Sean McCarroll from Balcas for their tribute to Tom—a bespoke bench crafted in his memory. Mr. Foster said: 'This bench is more than just a seat; it's a place for reflection, comfort, and connection. As visitors rest here, may they find solace and draw inspiration from Tommy's life and the love he shared with all who knew him. 'Tommy's absence leaves a void, but his spirit lives on in the laughter we shared and the memories we cherish. Let this bench serve as a lasting tribute to a remarkable man whose impact will be felt for generations to come.' The opening of Inis Ceithleann Retreat represents a beacon of hope for those affected by Pulmonary Fibrosis, ensuring that families have a place of peace, sanctuary, and renewal in their time of need. Tom McMillan, Chair of Pulmonary Fibrosis NI (PFNI), opened the event with a welcome and introduction. Dr. Nadia Chadkuri, a PFNI Trustee, also spoke, followed by patient and trustee Una McMillan. Paddy McNamara, a patient and transplant recipient, shared his experiences and insights as an ambassador for PFNI. Representatives from the community and political parties also attended the opening.
